Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users

Journal of Clinical Virology

Volumn 66, Issue , 2015, Pages 15-18

  Mixson Hayden, Tonya ^a   Dawson, George J ^b   Teshale, Eyasu ^a   Le, Thao ^a   Cheng, Kevin ^b   Drobeniuc, Jan ^a   Ward, John ^a   Kamili, Saleem ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

HCV core antigen; HCV RNA; HCV screening

Indexed keywords

HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; UNCLASSIFIED DRUG; VIRUS RNA; CORE PROTEIN; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS; VIRUS ANTIGEN;

ARTICLE; BLOOD DONOR; DIAGNOSTIC VALUE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; INTRAVENOUS DRUG ABUSE; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; BLOOD; COMPLICATION; DIAGNOSTIC TEST; DRUG USE; EVALUATION STUDY; MASS SCREENING; PLASMA; PROCEDURES; SUBSTANCE ABUSE; UNITED STATES; VIROLOGY;

ANTIGENS, VIRAL; BLOOD DONORS; DIAGNOSTIC TESTS, ROUTINE; DRUG USERS; HEPATITIS C; HUMANS; IMMUNOASSAY; MASS SCREENING; PLASMA; SENSITIVITY AND SPECIFICITY; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; VIRAL CORE PROTEINS;

EID: 84926685157     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2015.02.015     Document Type: Article

References (39)

1. Testing for HCV infection: an update of guidance for clinicians and laboratorians MMWR Morbidity and mortality weekly report, 62, 2013, 362-365.
2. Takahashi K., Okamoto H., Kishimoto S., Munekata E., Tachibana K., Akahane Y., et al. Demonstration of a hepatitis C virus-specific antigen predicted from the putative core gene in the circulation of infected hosts. J. Gen. Virol. 1992, 73(Pt 3):667-672.
3. Tanaka T., Lau J.Y., Mizokami M., Orito E., Tanaka E., Kiyosawa K., et al. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viremia. J. Hepatol. 1995, 23:742-745.
4. Morota K., Fujinami R., Kinukawa H., Machida T., Ohno K., Saegusa H., et al. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J. Virol. Methods 2009, 157:8-14.
5. Aoyagi K., Ohue C., Iida K., Kimura T., Tanaka E., Kiyosawa K., et al. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J. Clin. Microbiol. 1999, 37:1802-1808.
6. Leary T.P., Gutierrez R.A., Muerhoff A.S., Birkenmeyer L.G., Desai S.M., Dawson G.J. A chemiluminescent, magnetic particle-based immunoassay for the detection of hepatitis C virus core antigen in human serum or plasma. J. Med. Virol. 2006, 78:1436-1440.
7. Lee S.R., Peterson J., Niven P., Bahl C., Page E., DeLeys R., et al. Efficacy of a hepatitis C virus core antigen enzyme-linked immunosorbent assay for the identification of 'window-phase' blood donations. Vox sanguinis 2001, 80:19-23.
8. Muerhoff A.S., Jiang L., Shah D.O., Gutierrez R.A., Patel J., Garolis C., et al. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion 2002, 42:349-356.
9. Zhang H.Q., Li S.B., Wang G.H., Chen K., Song X.G., Feng X.Y. Detection of hepatitis C virus core antigen for early diagnosis of hepatitis C virus infection in plasma donor in China. World J. Gastro.: WJG 2007, 13:2738-2742.
10. Kesli R., Polat H., Terzi Y., Kurtoglu M.G., Uyar Y. Comparison of a newly developed automated and quantitative hepatitis C virus (HCV) core antigen test with the HCV RNA assay for clinical usefulness in confirming anti-HCV results. J. Clin. Microbiol. 2011, 49:4089-4093.
11. Kuo Y.H., Chang K.C., Wang J.H., Tsai P.S., Hung S.F., Hung C.H., et al. Is hepatitis C virus core antigen an adequate marker for community screening. J. Clin. Microbiol. 2012, 50:1989-1993.
12. Mederacke I., Wedemeyer H., Ciesek S., Steinmann E., Raupach R., Wursthorn K., et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 2009, 46:210-215.
13. Medici M.C., Furlini G., Rodella A., Fuertes A., Monachetti A., Calderaro A., et al. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 2011, 51:264-269.
14. Miedouge M., Saune K., Kamar N., Rieu M., Rostaing L., Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 2010, 48:18-21.
15. Ross R.S., Viazov S., Salloum S., Hilgard P., Gerken G., Roggendorf M. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J. Clin. Microbiol. 2010, 48:1161-1168.
16. Gonzalez V., Padilla E., Diago M., Gimenez M.D., Sola R., Matas L., et al. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin*. J. Viral Hepatitis 2005, 12:481-487.
17. Maynard M., Pradat P., Berthillon P., Picchio G., Voirin N., Martinot M., et al. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients' response to therapy. J. Viral Hepatitis 2003, 10:318-323.
18. Tanaka E., Kiyosawa K., Matsumoto A., Kashiwakuma T., Hasegawa A., Mori H., et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. Hepatol. (Baltimore, Md) 1996, 23:1330-1333.
19. Tedder R.S., Tuke P., Wallis N., Wright M., Nicholson L., Grant P.R. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response. J. Viral Hepatitis 2013, 20:65-71.
20. Park Y., Lee J.H., Kim B.S., Kim do Y., Han K.H., Kim H.S. New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification. J. Clin. Microbiol. 2010, 48:2253-2256.
21. Yuksel P., Caliskan R., Ergin S., Aslan M., Celik D.G., Saribas S., et al. New approaches to in vitro diagnosis of hepatitis C infection a reason for post transfusion hepatitis: diagnostic value of determination of hepatitis C virus core antigen. Transf. Apher. Sci.: Off. J. World Apher. Assoc.: Off. J. Eur. Soc. Haemapheresis 2011, 45:247-250.
22. Ottiger C., Gygli N., Huber A.R. Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 2013, 58:535-540.
23. Jewett A., Smith B.D., Garfein R.S., Cuevas-Mota J., Teshale E.H., Weinbaum C.M. Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. J. Clin. Virol. 2012, 54:213-217.
24. Simmonds P. Genetic diversity and evolution of hepatitis C virus -15 years on. J. Gen. Virol. 2004, 85:3173-3188.
25. I. MiniTab. Minitab Statistical Software Release 16 for Windows. State College, PA, 2009.
26. Nubling, Unger G., Chudy M., Raia S., Lower J. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002, 42:1037-1045.
27. Shah D.O., Chang C.D., Jiang L.X., Cheng K.Y., Muerhoff A.S., Gutierrez R.A., et al. Combination HCV core antigen and antibody assay on a fully automated chemiluminescence analyzer. Transfusion 2003, 43:1067-1074.
28. Chakravarti A., Chauhan M.S., Dogra G., Banerjee S., Hepatitis C. Virus core antigen assay: can we think beyond convention in resource limited settings?. Braz. J. Infect. Dis.: an Off. Publ. Braz. Soc. Infect. Dis. 2013, 17:369-374.
29. Fabrizi F., Lunghi G., Aucella F., Mangano S., Barbisoni F., Bisegna S., et al. Novel assay using total hepatitis C virus (HCV) core antigen quantification for diagnosis of HCV infection in dialysis patients. J. Clin. Microbiol. 2005, 43:414-420.
30. Seme K., Poljak M., Babic D.Z., Mocilnik T., Vince A. The role of core antigen detection in management of hepatitis C: a critical review. J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 2005, 32:92-101.
31. Tanaka E., Ohue C., Aoyagi K., Yamaguchi K., Yagi S., Kiyosawa K., et al. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology (Baltimore, Md) 2000, 32:388-393.
32. Zanetti A.R., Romano L., Brunetto M., Colombo M., Bellati G., Tackney C., Total H.C.V. Core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. J. Med. Virol. 2003, 70:27-30.
33. Ticehurst J.R., Hamzeh F.M., Thomas D.L. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J. Clin. Microbiol. 2007, 45:2426-2433.
34. Rodriguez-Torres M., Sulkowski M.S., Chung R.T., Hamzeh F.M., Jensen D.M. Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J. Viral Hepatitis 2010, 17:139-147.
35. Santantonio T., Fasano M., Sinisi E., Guastadisegni A., Casalino C., Mazzola M., et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J. Hepatol. 2005, 42:329-333.
36. Corey K.E., Ross A.S., Wurcel A., Schulze Zur Wiesch J., Kim A.Y., Lauer G.M., et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin. Gastroenterol. Hepatol.: Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2006, 4:1278-1282.
37. Bunchorntavakul C., Jones L.M., Kikuchi M., Valiga M.E., Kaplan D.E., Nunes F.A., et al. Distinct features in natural history and outcomes of acute hepatitis C. J. Clin. Gastroenterol. 2014.
38. Alanko Blome M., Bjorkman P., Molnegren V., Hoglund P., Widell A., Hepatitis C. Viremia patterns in incident hepatitis C infection and one year later in 150 prospectively tested persons who inject drugs. PLoS One 2014, 9:e97022.
39. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., et al.Hepatitis C. Viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science (New York, NY) 1998, 282:103-107.